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Abstract
Objectives To determine if patients with rheumatoid arthritis have
increased risk of atrial fibrillation and stroke.
Design Longitudinal nationwide register based cohort study.
Setting Inpatient and outpatient hospital care in Denmark from 1997 to
2009.
Participants Entire Danish population aged over 15 years without
rheumatoid arthritis, atrial fibrillation, or stroke before 1997. Participants
with rheumatoid arthritis were identified by individual level linkage of
diagnoses and rheumatoid arthritis treatment.
Main outcome measures Rates of atrial fibrillation and stroke.
Results Of 4 182 335 participants included in the cohort, 18 247 were
identified as having rheumatoid arthritis during follow-up, with a mean
age at disease onset of 59.2 years and a median follow-up of 4.8 years.
A total of 156 484 people, including 774 with rheumatoid arthritis, were
diagnosed as having atrial fibrillation (age and sex matched event rates
of 8.2 per 1000 person years in rheumatoid arthritis patients and 6.0 per
1000 person years in the general population), with an adjusted incidence
rate ratio of 1.41 (95% confidence interval 1.31 to 1.51). In addition, 165
343 people, including 718 with rheumatoid arthritis, had a stroke (7.6
per 1000 person years in rheumatoid arthritis and 5.7 per 1000 person
years in the general population), with a resultant rate ratio of 1.32 (1.22
to 1.42). For both atrial fibrillation and stroke, relative risks were increased
in all strata based on thirds of sex and age, with higher relative risks in
younger patients but higher absolute risk differences in older patients.
Conclusions Rheumatoid arthritis was associated with an increased
incidence of atrial fibrillation and stroke. The novel finding of increased
risk of atrial fibrillation in rheumatoid arthritis suggests that this arrhythmia
is relevant in cardiovascular risk assessment of these patients.
Introduction
Rheumatoid arthritis has been shown to be associated with
substantialcardiovascularcomorbidity,butmostoftheavailable
evidence originates from studies on the risk of myocardial
infarction and cardiovascular mortality.
1-3 In contrast to the risk
of myocardial infarction related to rheumatoid arthritis, the
results from studies on risk of stroke have been inconsistent,
which may reflect the diverse causes of stroke, including
atherothrombosis, thromboembolism, and haemorrhage, but
also differences in study designs and characteristics of
rheumatoidarthritispopulationsexamined.
2-10Atrialfibrillation
is an important and modifiable risk factor for stroke.
11 To our
knowledge, however, studies on the incidence of atrial
fibrillation, and its effect on the risk of stroke, in patients with
rheumatoid arthritis have not been reported, even though the
incidence of atrial fibrillation is known to be increased by
severalfactorsthataremoreprevalentinpeoplewithrheumatoid
arthritis, such as heart failure, ischaemic heart disease, and
smoking.
4 12-14 Furthermore, studies have suggested that
inflammation plays a role in the development of atrial
fibrillation.
15 In this study, therefore, we examined the risk of
atrialfibrillationandstrokeassociatedwithrheumatoidarthritis
in a Danish nationwide register based cohort study from 1997
to 2009.
Methods
Study cohort and data sources
Our study cohort consisted of all Danish inhabitants aged over
15 years on 1 January 1997, as identified through the Danish
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Research
RESEARCHcivilregistrationsystem.InDenmark,allpeopleareissuedwith
a unique and permanent personal identifier at birth, which
enabled data from several individual level Danish nationwide
registers to be combined. Data on morbidity came from the
national patient register, where diagnoses from all hospital
admissions (from 1978) and outpatient activities (from 1995)
are listed according to the ICD-8 (international classification
ofdiseases,8threvision)codesuntil1994andICD-10thereafter.
Here, dates and institutions providing each patient contact are
recorded along with one primary and, if appropriate, one or
more secondary diagnoses. All prescriptions dispensed from
Danish pharmacies have been registered since 1995 in the
Danish register of medicinal product statistics, which we used
to obtain information on drug treatment at an individual level,
including the anatomical therapeutic chemical class, drug
strength, quantity, and date of dispensed prescription.
Information on income and migration were available through
Statistics Denmark. All the registers used have nationwide
coverage; as reporting of data is obligatory and linked to
financial reimbursements, they are effectively complete.
16 17
Cohort entry and follow-up
We followed the cohort from baseline in 1997 until occurrence
ofastudyendpoint,emigration,ordeathor31December2009,
whichever came first. We excluded people with a diagnosis of
rheumatoidarthritis,atrialfibrillation,orstrokebeforebaseline
fromthestudycohort.Wemonitoredcohortparticipantsforthe
development of rheumatoid arthritis as determined by ICD-10
codes M05-M06 in combination with a dispensed prescription
ofdiseasemodifyingantirheumaticdrugswithinoneyearbefore
or after the time of diagnosis (see web appendix for anatomical
therapeutic chemical codes used). This method has previously
been validated with both sensitivity and specificity of greater
than 80%.
18 We used the last of either the prescription date or
the date of diagnosis as the starting point for the time at risk
with rheumatoid arthritis.
End points and potential endpoint predictors
We detected cases of atrial fibrillation by admissions with the
ICD codeI48 (ICD-10)andstrokeby admissions withI60, I61,
I63, and I64 (ICD-10). Both end points have been validated in
the Danish patient registry previously.
19-22
Atstudybaselineon1January1997,wecharacterisedallcohort
participantswithregardtopotentialendpointpredictors.Onthe
basis of dispensed prescriptions during 1996, we established
baseline cardiovascular drug use, as well as the presence of
diabetes by the use of glucose lowering drugs, as previously
done.
23 We identified hyperthyroid disease by dispensed
antithyroid drugs. We defined hypertension as the concurrent
useofatleasttwoantihypertensiveagents.
24Weestablishedthe
presenceofheartfailure,ischaemicheartdisease,heartsurgery,
valvular disease, cardiomyopathy, and chronic obstructive
pulmonarydiseasebyoccurrenceofrespectiveICDcodesbefore
baseline. Details of anatomical therapeutic chemical and ICD
codes used in the above definitions are listed in the web
appendix.
Tohaveanon-inflammatoryrheumaticdiseaseasacomparator
to rheumatoid arthritis and to evaluate the potential influence
ofsurveillancebias,wealsoidentifiedparticipantswhoreceived
a primary diagnosis of osteoarthritis (ICD-10: M15-19, M47).
We calculated an index of socioeconomic status from 1 to 5 on
the basis of participants’ income in the years 1992-6
standardised by age.
For both end points, we did supplementary analyses in which
we matched each patient with rheumatoid arthritis with four
controls with same sex and year of birth. We then determined
the characteristics described above in each set of matched
participants at the index date of the patient with rheumatoid
arthritis.
Statistical analysis
To obtain an accurate allocation of exposure time, people who
developed rheumatoid arthritis contributed with time at risk in
the reference group until the rheumatoid arthritis index date;
that is, outcomes before the index date would be allocated to
the reference group. We calculated overall as well as sex and
age specific absolute incidence rates (IR) of atrial fibrillation
and stroke. We calculated sex and age specific attributable risk
with rheumatoid arthritis as exposure (IRrheumatoid arthritis−IRgeneral
population/IRrheumatoidarthritis). We fitted multivariable Poisson regression
models to estimate incidence rates ratios for atrial fibrillation
andstrokeinpatientswithrheumatoidarthritiswiththegeneral
population as reference. We also analysed the risk of atrial
fibrillation and stroke including sex, age, calendar year, and
socioeconomic index as covariates by proportional hazard
regression models (Cox regression), which yielded identical
risk estimates to those from Poisson regression. However, we
preferred Poisson regression models because detailed analyses
using Cox regression were unfeasible owing to the large size
of the study dataset. As analyses showed interaction between
age and rheumatoid arthritis status in models evaluating stroke
risk, and to assess potential effects of difference in sex
distribution, we present both overall and age/sex stratified
regression models. In addition to the follow-up time, we used
agedividedintofiveyearintervals(overallmodel)andcalendar
year (overall and age stratified models) as time scales. In the
matched design study, we estimated risk as hazard ratios from
Cox regression analyses with the matched groups considered
asindividualstrata.Wetestedproportionalhazardsassumptions
and found them to be valid.
We report continuous variables as means with standard
deviations and categorical data as frequencies and percentages,
unless otherwise indicated. We considered a two tailed P value
less than 0.05 to be significant and provide 95% confidence
intervals. We used SAS version 9.2 for data management and
Stata version 11.1 for statistical analysis. The study was
conducted and reported in accordance with the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) recommendations.
25
Results
FromthetotalDanishpopulation,4282752peoplewereeligible
to enter the study cohort. Figure 1⇓ shows a flow chart of the
study population, and table 1⇓ shows baseline characteristics
of people who developed rheumatoid arthritis and the general
population. A total of 18 247 people were identified as having
rheumatoid arthritis, with a female predominance of
approximately 70%, a mean age at disease onset of 59.2 (SD
14.1) years and a median follow-up of 4.8 (interquartile range
2.3-8.1) years. During follow-up, 165 343 people, including
718 with rheumatoid arthritis, had a stroke and 156 484 people,
including 774 with rheumatoid arthritis, were diagnosed as
having atrial fibrillation. This corresponded to incidence rates
ofbothendpointsthatweresignificantlyhigherinpatientswith
rheumatoid arthritis than in the general population, regardless
of strata based on sex or age (table 2⇓). Figures 2⇓ and 3⇓
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RESEARCHillustrate the relations between age and rates of atrial fibrillation
and stroke in more detail.
Atrial fibrillation
The overall incidence of atrial fibrillation was approximately
40% higher in rheumatoid arthritis patients than in the general
population (age and sex matched event rates of 8.2 and 6.0 per
1000personyears).Womenwereatslightlyhigherrelativerisk
thanmen,andtherelativeriskofatrialfibrillationwasmarkedly
increased in the youngest age groups; the absolute risk
attributable to rheumatoid arthritis ranged from 25% in the
oldest to 70% in the youngest age group.
The change in risk estimates after inclusion of baseline
cardiovascular drug use and comorbidity in the analysis was
negligible (table 3⇓). The risk of atrial fibrillation associated
with rheumatoid arthritis was somewhat reduced when all
cardiovascular drug use and comorbidity was updated during
follow-up (incidence rate ratio 1.24, 95% confidence interval
1.15 to 1.35). Interestingly, this effect was primarily driven by
inclusion of loop diuretics (incidence rate ratio 1.25, 1.16 to
1.34, when these were included alone). To assess the influence
of surveillance bias as a result of regular outpatient visits for
rheumatoidarthritis,wedidseveralsensitivityanalyses.Firstly,
we excluded cases of atrial fibrillation within the first month of
the rheumatoid arthritis index (82 events) to reduce the effect
ofincreasedsurveillanceinrelationtothediagnosis(consequent
incidence rate ratio 1.39, 1.30 to 1.49). Secondly, we repeated
analyses including only admissions with atrial fibrillation as
the primary diagnosis (consequent incidence rate ratio 1.43,
1.29 to 1.59). Thirdly, we excluded users of vitamin K
antagonists at baseline and during follow-up to diminish the
contribution of patients with unreported prevalent atrial
fibrillation (consequent incidence rate ratio 1.43, 1.33 to 1.53).
Fourthly, we assessed risk of atrial fibrillation in patients with
osteoarthritis (incidence rate ratio 1.17, 1.08 to 1.24), which
wassignificantlylowercomparedwithpatientswithrheumatoid
arthritis,eventhoughosteoarthritisislikelytoleadtoincreased
surveillance. Fifthly, we restricted analysis to follow-up of
approximately half a million patients who were diagnosed as
havingcardiovasculardiseaseasdefinedintable1⇓(consequent
incidence rate ratio 1.43, 1.24 to 1.65).
Stroke
Age and sex matched stroke rates were 7.6 per 1000 person
years in rheumatoid arthritis patients and 5.7 per 1000 person
yearsinthegeneralpopulation,whichcorrespondedtoanoverall
increase in risk of 30%. Similar to the findings with atrial
fibrillation, the relative risk was highest in the younger age
groups, but with increasing absolute difference in incidence
rates with increasing age up to 80 years and above (fig 3⇓). By
further analogy with the atrial fibrillation results, stroke risk
variedminimallyinoursensitivityanalysesandwhencompared
with that in patients with osteoarthritis.
Concerning contribution of atrial fibrillation to stroke risk, we
foundthatupdatingatrialfibrillationdiagnosesduringfollow-up
slightly lowered the risk estimate for rheumatoid arthritis
(incidence rate ratio 1.29, 1.20 to 1.39), which was consistent
with the finding of no significant interaction between atrial
fibrillation and rheumatoid arthritis (incidence rate ratio 0.92;
P=0.49) and the limited follow-up in the group with both
rheumatoid arthritis and atrial fibrillation.
Supplemental matched design study
In general, baseline characteristics showed modestly increased
frequencies of cardiovascular drug use and comorbidity in
patients with rheumatoid arthritis (table 4⇓). The results from
Coxregressionanalysescorroboratedthefindingsoftheprimary
analysis (table 5⇓). Successive inclusion of main groups of
covariatesonlymarginallychangedtheriskestimatesforstroke,
whereas a small decrease in risk of atrial fibrillation was
observed when baseline cardiovascular drug use was included.
This decrease was exclusively driven by the inclusion of loop
diuretic use.
Discussion
This study examined the incidence of atrial fibrillation and
stroke in a Danish nationwide register based cohort including
more than 18 000 patients with rheumatoid arthritis who were
followed for up to 13 years. The incidence of atrial fibrillation
wasfoundtobe40%higherinrheumatoidarthritispatientsthan
in the general population, and the risk of stroke in rheumatoid
arthritis patients was roughly 30% higher. For both atrial
fibrillation and stroke, we saw remarkable threefold increases
intherelativerisksinpatientswithrheumatoidarthritisyounger
than 50, as also indicated by the high proportion of the risk that
wasattributabletorheumatoidarthritisinyoungcomparedwith
older patients. Nonetheless, the absolute differences in rates of
atrial fibrillation and stroke between people with and without
rheumatoid arthritis were highest in the oldest patients.
Comparison with other studies
To our knowledge, the incidence of atrial fibrillation has not
previously been examined in a large rheumatoid arthritis
population, and only a very limited number of small clinical
studies have examined the occurrence of arrhythmias in these
patients, with no reports on atrial fibrillation.
26-28 Although the
increased incidence of atrial fibrillation in patients with
rheumatoid arthritis is a novel finding that must be tested in
other cohorts, several lines of evidence support this result.
Firstly, mounting evidence indicates that heart failure is more
prevalent in rheumatoid arthritis compared with controls.
13 14
As heart failure is strongly associated with atrial fibrillation
(and vice versa), this observation may explain some of the
increased risk of atrial fibrillation, as also suggested by the fact
that in our study estimates atrial fibrillation risk were primarily
affected by time varying confounder adjustment for loop
diuretics, which are routinely used for heart failure. Secondly,
patients with rheumatoid arthritis show increased arterial
stiffness, which is a risk factor for heart failure and atrial
fibrillation.
29-31 Thirdly, recent reports have also suggested use
of glucocorticoids and non-steroidal anti-inflammatory drugs
as a risk factor for atrial fibrillation; however, although such
associations could explain part of the increased risk of atrial
fibrillation in rheumatoid arthritis, these studies were cross
sectionalintheirdesignandsubjecttoconfoundingbyindication
(that is, the drugs were prescribed for diseases associated with
atrial fibrillation including rheumatoid arthritis and chronic
obstructivepulmonarydisease).
32 33Fourthly,inflammationitself
has been proposed as playing a role in development of atrial
fibrillation, and increased circulating concentrations of
inflammatory markers such as C reactive protein have been
associated with atrial fibrillation and lower rates of successful
cardioversion.
15 34 35 Increased P wave dispersion in
electrocardiography, which is considered to be a predictor of
atrial fibrillation, also occurs more frequently in people with
rheumatoid arthritis and seems to be highly correlated with the
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36 37Thesumofcurrentevidence
thereforeclearlysuggeststhatchronicinflammationcontributes
to the increased risk of atrial fibrillation in patients with
rheumatoid arthritis.
In contrast to consistent data indicating an increased risk of
myocardial infarction in rheumatoid arthritis, reports on the
rheumatoid arthritis related risk of stroke are conflicting. One
recent meta-analysis concluded that the risk of myocardial
infarction,butnotstroke,wassignificantlyincreasedinpatients
with rheumatoid arthritis, whereas another found a twofold
increased risk of both stroke and myocardial infarction.
2 3 The
twomostrecentlargecohortstudiesinthisareaofresearchalso
had contradictory conclusions.
6 10 As their main difference was
in the duration of rheumatoid arthritis at cohort entry, which
probably also reflected differences in the rheumatoid arthritis
treatment strategy (with more aggressive treatment being the
mainstay of modern management), the risk of stroke might be
more dependent on the duration of rheumatoid arthritis and its
treatment than is the case for the risk of myocardial infarction.
We were not able to specifically explore this hypothesis in our
study, not least because data on duration of symptoms before
diagnosis of rheumatoid arthritis were lacking. However, the
marked age dependent relative risk of stroke attributable to
rheumatoid arthritis may offer another explanation for the
inconsistent results in previous studies, as the differences in
stroke risk could be caused by variations in age distributions in
the rheumatoid arthritis populations studied.
2-10 To what extent
the increased risk of atrial fibrillation contributed to the
increased risk of stroke in rheumatoid arthritis patients was not
clear owing to a limited follow-up in these cases, but no major
effectmodificationwasnoted,whichindicatedthatrheumatoid
arthritis was a risk factor for stroke beyond the increased risk
of atrial fibrillation.
Theincreasedriskofstrokeinpatientswithrheumatoidarthritis
is most likely to represent a multifactorial process in which
accelerated inflammation driven atherothrombosis, a higher
prevalenceofclassicalriskfactors,adverseeffectsofrheumatoid
arthritis treatment, and increased risk of atrial fibrillation play
important roles.
12 30 38 39 At the time of diagnosis, patients with
rheumatoid arthritis already have an increased prevalence of
carotid plaques compared with controls.
40 41 Also, endothelial
dysfunction and increased vascular stiffness, which are
predictors of atherosclerotic disease including stroke, are seen
in these patients and may improve after anti-inflammatory
treatment, although the very same treatment may augment the
cardiovascular risk through other pathways (for example,
non-steroidal anti-inflammatory drugs, glucocorticoids, and
cytotoxic disease modifying antirheumatic drugs).
30 38 42 43
Clinical implications
Intherecentyears,thecareofpatientswithrheumatoidarthritis
hasbeenextendedtocovertheincreasedcomorbidity,especially
thatduetocardiovasculardisease.Newlydevelopedguidelines
recommend annual screening for cardiovascular risk factors in
patients with rheumatoid arthritis, to counter the reported
increased risk of, for example, acute myocardial infarction and
stroke.
38 As no evidence has been available on the risk of atrial
fibrillation, the focus has primarily been on standard primary
prevention of hard end points by traditional risk score
assessment.Overall,ourfindingscorrespondedtoonenewcase
ofatrialfibrillationper12rheumatoidarthritispatientsfollowed
for 10 years after diagnosis. Given the augmented risk of atrial
fibrillation (which is often asymptomatic) and the ample
opportunity for diagnosis of arrhythmia at the recommended
annual screening appointments, we suggest that the clinical
focus should here include screening for atrial fibrillation, not
least in light of the relative easiness of such screening, the risk
of stroke with subsequent disability and societal burden, and
the powerful effect of anticoagulation treatment. Moreover,
these findings may indicate that rheumatoid arthritis can add to
future risk stratification scores for stroke in patients with atrial
fibrillation and lower the threshold for anticoagulation. As
inflammation is likely to play a significant role in the
pathogenesis of atrial fibrillation and stroke, this study also
underlines the importance of rigorous control of inflammation
with disease modifying antirheumatic drugs, not only for the
management of joint symptoms but also to reduce the need for
drugs with potential adverse cardiovascular effects and,
ultimately,todiminishtheinflammationdrivenatherothrombotic
process.
Strengths and weaknesses
Although our results were strengthened by a high number of
unselected patients with rheumatoid arthritis, an untruncated
age span, and a contemporary study cohort, several important
limitations should be considered when evaluating the findings.
Given the register based approach, people were identified as
having rheumatoid arthritis by dispensed prescriptions for
disease modifying antirheumatic drugs and recorded diagnoses
rather than by use of formal clinical criteria. Therefore, cases
of rheumatoid arthritis who were not treated with such drugs as
well as cases who did not attend a hospital clinic at any time
during the study were excluded. These cases may have a less
active disease and hence a lower risk of comorbidity, but they
probablyrepresentasmallminorityofpatients,consideringthe
national treatment guidelines in the study period. Conversely,
the risk could be underestimated by examining treated patients
only, especially as inflammation is likely to be an important
contributor to both outcomes. Of note, the incidence of
rheumatoid arthritis in this study corresponded closely to those
in previous Danish clinic based incidence studies.
44 The
identification of study end points relied on diagnoses from
hospital admissions. Whereas stroke usually leads to hospital
admission (and thus capture in the registers), this is not always
the case for atrial fibrillation. However, the sensitivity of the
diagnosisofatrialfibrillationinthenationalpatientregisterwas
previouslyfoundtobe88%,andthespecificitywas88-99%.
19-21
Also, the incidence of atrial fibrillation identified in this study
was similar to the findings in a large contemporary European
population based study.
45
Surveillancebiasduetomorefrequentexaminationsinpatients
withrheumatoidarthritismayhaveexaggeratedtheriskofatrial
fibrillation related to rheumatoid arthritis and was therefore
assessed in several sensitivity analyses. Importantly, when
analysis was restricted to cases in which atrial fibrillation was
the primary cause of admittance, which are less likely to be
differential with regard to rheumatoid arthritis status as such
cases are most often due to sudden onset of significant
symptoms, the results were not affected. Also, findings were
consistentinpeoplewithpreviouscardiovasculardisease,among
whom both rheumatoid arthritis patients and controls would
arguably have similar level of surveillance for the diagnosis of
atrial fibrillation. Moreover, until recently,
38 cardiovascular
examinations including pulse assessment and cardiac
auscultation were usually restricted to initial evaluation at
diagnosis of rheumatoid arthritis, but exclusion of end points
within the first month after diagnosis had no effect on our
findings.
Another important consideration was whether our adjustments
forconfoundingfactorswereadequate.Ingeneral,wecontrolled
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scales and by presenting age stratified results. In addition, the
main results were similar in age and sex matched models in
which length of follow-up was similar in the two groups,
averaging five years. We lacked information on several
important cardiovascular risk factors, and as patients with
rheumatoid arthritis may have a higher prevalence of smoking,
dyslipidaemia, and reduced physical exercise, availability of
suchinformationcouldchangetheriskestimates,althoughsome
of this unmeasured confounding was probably controlled for
by inclusion of several cardiovascular drugs and comorbidities
in the analyses
Moreover, most of these confounders, such as heart failure and
dyslipidaemia, reduced physical exercise, and adverse effects
of antirheumatoid arthritis drugs are inherently prevalent in
rheumatoidarthritisandtosomeextentrepresentintermediaries
in the pathway from rheumatoid arthritis to stroke or atrial
fibrillation.Consequently,theirinclusioninouranalyseswould
tend to underestimate the risk of atrial fibrillation and stroke in
the average patient with rheumatoid arthritis.
Overall, these potential sources of bias and confounding were
inherent to the observational nature of our study and, despite
our attempts to identify their contributions to the results, we
cannot exclude the effects of additional unmeasured factors.
Conclusions
Thisstudyofmorethan18000patientswithrheumatoidarthritis
found a 40% increase in risk of atrial fibrillation and a 30%
increase in the risk of stroke. The augmented risk of stroke in
rheumatoidarthritisaddssignificantlytoexistingevidence,and
the novel finding of an increased incidence of atrial fibrillation
suggests that this arrhythmia is relevant in cardiovascular risk
assessment of these patients.
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RESEARCHTables
Table 1| Baseline characteristics. Values are numbers (percentages) unless stated otherwise
Rheumatoid arthritis (n=18 247) General population (n=4 164 088) Characteristic
12 726 (69.7) 2 121 459 (50.9) Female sex
52.4 (14.9) 45.6 (18.4) Mean (SD) age (years):
52.0 (15.2) 46.8 (19.2) Women
53.2 (14.0) 44.3 (17.6) Men
Comorbidity:
936 (5.1) 148 893 (3.6) Hypertension
101 (0.6) 27 221 (0.7) Heart failure
620 (3.4) 109 382 (2.6) Ischaemic heart disease
136 (0.7) 16 945 (0.4) Hyperthyroid disease
270 (1.5) 49 666 (1.2) Chronic obstructive pulmonary disease
101 (0.6) 16 363 (0.4) Heart surgery
368 (2.0) 71 288 (1.7) Diabetes
2.77 (1.39) 3.00 (1.41) Mean (SD) socioeconomic index
Cardiovascular drugs:
942 (5.2) 150 322 (3.6) β blocker
174 (1.0) 28 587 (0.7) Cholesterol lowering drug
740 (4.1) 119 704 (2.9) ACEI/ARB
592 (3.2) 93 711 (2.3) Calcium channel blocker
1 161 (6.4) 176 078 (4.2) Thiazide diuretic
695 (3.8) 130 861 (3.1) Loop diuretic
68 (0.4) 15 170 (0.4) Spironolactone
98 (0.5) 14 259 (0.3) Vitamin K antagonist
794 (4.4) 155 122 (3.7) Platelet inhibitor
ACEI=angiotensin converting enzyme inhibitor; ARB=angiotensin 2 receptor blocker.
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RESEARCHTable 2| Atrial fibrillation and stroke: numbers of events, time at risk, and risk estimates in general population and patients with rheumatoid
arthritis
Incidence rate ratio†
(95% CI)
Attributable
risk* (%)
Rheumatoid arthritis General population
Incidence (per
1000 py)
Time at risk
(1000 py) No
Incidence (per
1000 py)
Time at risk (1000
py) No
Atrial fibrillation
1.42 (1.32 to 1.52) 8.2 94.5 774 3.3 47 915 155 710 Total
Women (age in
years):
1.48 (1.36 to 1.62) 7.3 67.1 491 3.0 24 532 73 656 All
2.96 (1.48 to 5.93) 69 0.5 16.8 8 0.1 12 922 1 915 <50
1.86 (1.48 to 2.35) 49 2.9 24.6 72 1.5 6 387 9 502 50-65
1.26 (1.15 to 1.39) 25 16.0 25.8 411 11.9 5 223 62 239 >65
Men (age in years):
1.33 (1.19 to 1.50) 10.3 27.4 283 3.3 23 383 82 054 All
3.11 (1.62 to 5.98) 70 1.5 5.9 9 0.5 13 362 6 033 <50
1.72 (1.35 to 2.19) 45 6.1 10.7 65 3.3 6 296 21 064 50-65
1.24 (1.09 to 1.43) 24 19.4 10.8 209 14.7 3 725 54 957 >65
Stroke
1.33 (1.23 to 1.43) 7.6 94.8 718 3.4 47 884 164 625 Total
Women (age in
years):
1.33 (1.22 to 1.46) 6.8 67.2 457 3.3 24 500 81 772 All
3.11 (2.12 to 4.57) 67 1.7 16.7 26 0.5 12 905 6 555 <50
1.67 (1.36 to 2.06) 39 4.7 24.5 90 2.2 6 362 14 163 50-65
1.14 (1.02 to 1.26) 11 15.3 26.1 341 11.7 5 233 61 054 >65
Men (age in years):
1.34 (1.19 to 1.51)) 9.5 27.6 261 3.5 23 384 82 853 All
3.61 (2.05 to 6.36) 72 2.0 5.9 12 0.6 13 359 7 605 <50
1.70 (1.34 to 2.15) 40 6.4 10.7 68 3.8 6 285 23 861 50-65
1.21 (1.05 to 1.40) 16 16.4 11.0 181 13.7 3740 51 387 >65
py=person years.
*Rheumatoid arthritis as exposure.
†Adjusted for age, sex, and calendar year (age not included in age stratified model).
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RESEARCHTable 3| Atrial fibrillation and stroke: incidence rate ratio (95% CI) associated with rheumatoid arthritis
Stroke Atrial fibrillation Model
1.34 (1.24 to 1.44) 1.43 (1.33 to 1.53) Adjusted for sex, age, and calendar year
1.33 (1.23 to 1.43) 1.42 (1.33 to 1.53) Adjusted for above and socioeconomic status
1.32 (1.22 to 1.42) 1.41 (1.31 to 1.51) Adjusted for above and baseline cardiovascular drugs*
1.32 (1.22 to 1.42) 1.41 (1.31 to 1.51) Adjusted for above and baseline comorbidity*
*As listed in table 1 (baseline characteristics).
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RESEARCHTable 4| Supplementary matched design analysis of risk of atrial fibrillation and stroke: baseline characteristics. Values are numbers
(percentages) unless stated otherwise
P value for difference* Rheumatoid arthritis (n=18 247) General population (n=72 988) Characteristic
NA 12 726 (69.7) 50 904 (69.7) Female sex
Mean (SD) age (years):
NA 58.9 (14.8) 58.9 (14.8) Women
NA 60.1 (13.6) 60.1 (13.6) Men
Comorbidity:
<0.01 2 272 (12.5) 8 217 (11.3) Hypertension
<0.01 436 (2.4) 952 (1.3) Heart failure
<0.01 1 399 (7.7) 4 139 (5.7) Ischaemic heart disease
<0.01 388 (2.1) 1 150 (1.6) Hyperthyroid disease
<0.01 848 (4.6) 2 131 (2.9) Chronic obstructive pulmonary disease
<0.01 439 (2.4) 1 322 (1.8) Heart surgery
<0.01 967 (5.3) 3 174 (4.3) Diabetes
<0.01 2.98 (1.41) 3.02 (1.41) Mean (SD) socioeconomic index
Cardiovascular drugs:
<0.01 1 895 (10.4) 6 657 (9.1) β blocker
0.16 1 544 (8.5) 5 955 (8.2) Cholesterol lowering drug
<0.01 2 581 (14.1) 9 029 (12.4) ACEI/ARB
<0.01 1 404 (7.7) 4 764 (6.5) Calcium channel blocker
<0.01 2 595 (14.2) 7 982 (10.9) Thiazide diuretic
<0.01 1 843 (10.1) 3 801 (5.2) Loop diuretic
<0.01 344 (1.9) 745 (1.0) Spironolactone
<0.01 444 (2.4) 697 (1.0) Vitamin K antagonist
<0.01 1 864 (10.2) 6 013 (8.2) Platelet inhibitor
ACEI=angiotensin converting enzyme inhibitor; ARB=angiotensin 2 receptor blocker; NA=not applicable.
*Unadjusted conditional (matched set) logistic regression.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e1257 doi: 10.1136/bmj.e1257 (Published 8 March 2012) Page 10 of 12
RESEARCHTable 5| Supplementary matched design analysis of risk of atrial fibrillation and stroke: hazard ratio (95% CI) associated with rheumatoid
arthritis
Stroke Atrial fibrillation Model
1.41 (1.28 to 1.55) 1.48 (1.36 to 1.62) Adjusted for calendar year (sex and age matched)
1.40 (1.28 to 1.54) 1.47 (1.35 to 1.61) Adjusted for above and socioeconomic status
1.39 (1.26 to 1.54) 1.40 (1.28 to 1.54) Adjusted for above and baseline cardiovascular drugs*
1.38 (1.26 to 1.52) 1.39 (1.27 to 1.53) Adjusted for above and baseline morbidity*
*As listed in table 4 (baseline characteristics).
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RESEARCHFigures
Fig 1 Flow chart of study population
Fig 2 Rates of atrial fibrillation in general population and patients with rheumatoid arthritis
Fig 3 Rates of stroke in general population and patients with rheumatoid arthritis
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